Mansergh Gordon, Kota Krishna Kiran, Stephenson Rob, Hirshfield Sabina, Sullivan Patrick
Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Oak Ridge Institute for Science and Education, Oak Ridge, TN, USA.
J Int AIDS Soc. 2021 Jan;24(1):e25664. doi: 10.1002/jia2.25664.
Daily oral pre-exposure prophylaxis (PrEP) is available and recommended for men who have sex with men (MSM) at risk for HIV infection. Other HIV prevention products are being developed, including long-acting injectable (LAI) and event-based oral and topical formulations. Understanding preferences for potential products by MSM can help direct further development of prevention messaging.
We present baseline data from HIV-negative participants enrolled in the US Mobile Messaging for Men (M-cubed) Study. Participants were asked their likelihood of and rank order preference for using daily oral PrEP and various potential prevention products (one- to -three-month injections, 2-1-1 sexual event oral dosing, anal or penile gel, or anal suppository), and their sociodemographic characteristics. Bivariate and multivariable logistics regression assessed demographic associations with likelihood of use and rank order preference.
Overall, most MSM reported a likelihood of using LAI (74%), sexual event-based pills (67%) and penile gel (64%). Men who reported recent unprotected (condomless and PrEPless) anal sex most preferred a penile gel formulation (74%), followed closely by LAI and event-based pills (73% each). Current PrEP users (vs. non-users) had greater odds of reporting likelihood to use LAI (AOR = 3.29, 95% CI = 2.12 to 5.11), whereas men reporting recent unprotected anal sex had a greater odds of likelihood to use a penile gel (AOR = 1.79, 95% CI = 1.27 to 2.52) and an anal suppository (AOR = 1.48, 95% CI = 1.08 to 2.02). Hispanic/Latino (vs. White) MSM (AOR = 2.29, 95% CI = 1.40 to 3.73) and, marginally, Black MSM (AOR = 1.54, 95% CI = 1.00 to 2.38) had greater odds of reporting likelihood to use penile gel. Similar patterns were found for rank ordering preference of products, including condoms.
Most MSM were interested in using various potential future HIV prevention products, especially LAI. However, two typologies of potential users emerged: men who prefer sexual event-based methods (condoms, event-based pill, sexual gels and suppositories) and men who prefer non-sexual event-based methods (daily pill, LAI). Men who reported recent unprotected anal sex preferred a penile gel product most, followed closely by sexual event-based pills and LAI. Racial/ethnic differences were noted as well. These findings on product preferences can help in formulation development and messaging.
每日口服暴露前预防(PrEP)已可供有感染HIV风险的男男性行为者(MSM)使用并得到推荐。其他HIV预防产品也在研发中,包括长效注射剂(LAI)以及基于事件的口服和局部用制剂。了解MSM对潜在产品的偏好有助于指导预防信息的进一步开发。
我们展示了参与美国男性移动消息(M-cubed)研究的HIV阴性参与者的基线数据。参与者被问及使用每日口服PrEP和各种潜在预防产品(1至3个月注射剂、2-1-1性事件口服给药、肛门或阴茎凝胶或肛门栓剂)的可能性及偏好排序,以及他们的社会人口统计学特征。双变量和多变量逻辑回归评估了人口统计学与使用可能性及偏好排序之间的关联。
总体而言,大多数MSM报告有使用长效注射剂(74%)、基于性事件的药丸(67%)和阴茎凝胶(64%)的可能性。报告近期有无保护(未使用避孕套且未使用PrEP)肛交的男性最喜欢阴茎凝胶制剂(74%),紧随其后的是长效注射剂和基于性事件的药丸(均为73%)。当前使用PrEP的用户(与未使用者相比)报告使用长效注射剂可能性更大(调整后比值比[AOR]=3.29,95%置信区间[CI]=2.12至5.11),而报告近期有无保护肛交的男性使用阴茎凝胶(AOR=1.79,95%CI=1.27至2.52)和肛门栓剂(AOR=1.48,95%CI=1.08至2.02)的可能性更大。西班牙裔/拉丁裔(与白人相比)MSM(AOR=2.29,95%CI=1.40至3.73)以及勉强算上的黑人MSM(AOR=1.54,95%CI=1.00至2.38)报告使用阴茎凝胶可能性更大。在产品(包括避孕套)的偏好排序方面也发现了类似模式。
大多数MSM对使用各种未来潜在的HIV预防产品感兴趣,尤其是长效注射剂。然而,出现了两种潜在用户类型:喜欢基于性事件方法(避孕套、基于性事件的药丸、性凝胶和栓剂)的男性和喜欢非基于性事件方法(每日药丸、长效注射剂)的男性。报告近期有无保护肛交的男性最喜欢阴茎凝胶产品,紧随其后的是基于性事件的药丸和长效注射剂。还注意到了种族/民族差异。这些关于产品偏好的发现有助于制剂开发和信息传递。